No definition available.
Cardiomyopathy due to drugs and other external agents
CARDIOMYOPATHY_DRUGS_OTHER_EXTER_AGENTS
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
76 |
4. Check minimum number of eventsNone |
76 |
5. Include endpointsNone |
76 |
6. Filter based on genotype QC (FinnGen only) |
74 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF5
Similar endpoints
↥List of similar endpoints to
Cardiomyopathy due to drugs and other external agents
based on the number of shared cases.
Similar with more cases:
- Cardiomyopathies, Secondary/extrinsic
- Cardiomyopathy (excluding other)
- Cardiomyopathy
- Other heart diseases
- Other heart diseases, wide
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 370 | 194 | 172 |
| Only index persons | 288 | 154 | 134 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.00 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 58.64 | 60.72 | 56.11 |
| Only index persons | 57.79 | 60.94 | 54.16 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 74 | 50 | 24 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | 61.48 | 58.57 | 67.54 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 76
- Matched controls
- 760
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
I42.7
ICD-10 Finland
Cardiomyopathy due to drugs and other external agents
+∞
109.3
76
*
201
Kela drug reimbursment
Chronic cardiac insufficiency
32.0
48.7
38
23
I50.1
ICD-10 Finland
Left ventricular failure
45.9
31.1
38
16
I42.0
ICD-10 Finland
Dilated cardiomyopathy
59.8
29.8
34
10
C03DA01
ATC
spironolactone; oral
11.5
25.4
37
58
I50.9
ICD-10 Finland
Heart failure, unspecified
10.3
23.2
37
64
C09AA05
ATC
ramipril; oral
8.2
19.3
48
131
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
8.2
18.8
37
79
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
18.0
18.1
29
25
C03CA01
ATC
furosemide; systemic
7.0
15.9
50
164
I50.0
ICD-10 Finland
Congestive heart failure
15.6
15.0
25
23
I42.9
ICD-10 Finland
Cardiomyopathy, unspecified
38.5
14.7
18
6
H02AB02
ATC
dexamethasone; systemic
6.9
14.3
29
62
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
5.9
13.6
43
138
XFP20
NOMESCO Finland
Check up of cardiac pacemaker
14.6
11.9
20
18
AN1
HP
Coronary angiography
7.1
11.6
21
39
115
Kela drug reimbursment
Breast cancer
6.6
11.3
22
44
C09DX04
ATC
valsartan and sacubitril; oral
51.5
11.3
13
*
I47.2
ICD-10 Finland
Ventricular tachycardia
18.0
10.6
16
11
GD1AA
NOMESCO Finland
Thorax X-ray examination
5.0
10.2
53
239
289
Kela drug reimbursment
Combination product containing sacubitril and valsartan
63.4
9.9
11
*
L03AA02
ATC
filgrastim; parenteral
13.3
9.9
17
16
C07AB07
ATC
bisoprolol; oral
5.3
9.8
58
286
A03FA01
ATC
metoclopramide; systemic, rectal
4.6
9.7
37
131
PJD52
NOMESCO Finland
Block dissection of axillary lymph nodes
13.2
9.3
16
15
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
42.2
9.3
11
*
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
11.2
9.1
17
19
C01AA05
ATC
digoxin; systemic
9.0
9.0
19
27
FM1DE
NOMESCO Finland
Doppler ultrasound examination of heart
5.8
8.9
19
41
N02AA05
ATC
oxycodone; systemic
4.3
8.3
29
95
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
4.1
8.1
32
114
381
Kela drug reimbursment
Combination product containing sacubitril and valsartan
50.4
7.9
9
*
Z95.0
ICD-10 Finland
Presence of electronic cardiac devices
10.1
7.8
15
18
C85.9
ICD-10 Finland
Non-Hodgkin lymphoma, unspecified
88.4
7.6
8
*
250, ,
Kela drug reimbursment
33.5
7.3
9
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.8
7.2
19
49
Z45.0
ICD-10 Finland
Adjustment and management of cardiac devices
12.7
7.1
12
11
127
Kela drug reimbursment
Transplant complication
44.2
6.9
8
*
JN4BD
NOMESCO Finland
Extensive body CT
4.5
6.9
20
56
J01MA12
ATC
levofloxacin; systemic
3.9
6.8
27
95
TFC00
NOMESCO Finland
Catheterisation of right atrium or ventricle
76.0
6.5
7
*
L04AA01
ATC
[U] ciclosporin
+∞
6.3
6
*
HAC20
NOMESCO Finland
Total mastectomy
8.0
6.0
13
19
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
22
41
7.14
12.18
4.0
2.8
416.86
165.53
ng/l
1.10
22
34
27
91
4.05
7.30
7.3
2.9
0.80
0.81
mmol/l
0.18
27
84
34
143
3.49
6.53
2.3
2.0
2.70
3.28
mg/l
0.65
28
127
60
369
3.97
6.09
18.5
10.1
4.26
3.96
e9/l
0.37
55
326
46
259
2.97
5.05
3.1
2.6
163.95
93.93
ug/l
0.92
40
236
24
98
3.12
4.63
2.7
2.1
—
—
—
0
0
29
145
2.62
3.77
3.6
2.3
—
—
—
0
0
38
219
2.47
3.64
4.3
2.9
—
—
—
0
0
19
78
2.91
3.56
6.7
8.1
103.32
103.90
mmol/l
0.18
19
78
47
302
2.46
3.50
10.7
7.1
1.21
1.21
mmol/l
0.06
40
256
18
73
2.92
3.44
2.0
2.1
—
—
—
0
0
18
73
2.92
3.44
1.9
1.9
—
—
—
0
0
32
180
2.34
3.14
2.5
2.1
131.06
154.27
u/l
0.22
32
168
11
33
3.72
2.95
1.5
1.2
—
—
—
0
0
13
48
3.06
2.89
2.2
1.4
—
—
—
0
0
44
291
2.22
2.87
3.6
2.6
—
—
—
0
0
39
246
2.20
2.86
5.3
4.0
36.71
33.32
ng/l
0.10
34
172
5
7
7.54
2.59
1.4
1.3
240.20
283.90
u/l
—
5
7
19
93
2.39
2.48
3.7
2.5
1.94
1.21
e6/l
0.18
12
51
8
22
3.94
2.44
3.9
2.1
—
—
—
0
0
5
8
6.59
2.41
2.8
1.9
—
—
—
0
0
11
40
3.04
2.39
5.3
8.6
0.51
0.73
%
1.38
11
40
7
18
4.17
2.31
5.0
5.2
20.14
57.92
u/ml
—
7
18
8
24
3.60
2.25
1.4
2.5
—
—
—
0
0
7
19
3.95
2.21
2.4
2.1
—
—
—
0
0
7
19
3.95
2.21
2.1
2.1
—
—
—
0
0
7
20
3.74
2.11
2.9
1.8
—
—
—
0
0
7
20
3.74
2.11
1.4
1.3
—
—
—
0
0
42
300
1.89
1.96
25.0
14.0
1.72
1.23
inr
—
10
91
6
17
3.74
1.87
1.8
1.4
—
—
—
0
0
5
12
4.38
1.85
2.6
2.3
—
—
—
0
0
5
12
4.38
1.85
1.0
2.1
—
—
—
0
0
5
12
4.38
1.85
2.6
2.3
—
—
—
0
0
10
41
2.65
1.72
4.3
8.5
1.61
1.72
%
—
10
41
8
31
2.76
1.71
2.1
1.7
—
—
—
0
0
6
19
3.34
1.69
1.0
1.2
—
—
—
0
0
5
14
3.74
1.64
2.6
2.1
—
—
—
0
0
5
14
3.74
1.64
1.0
2.1
—
—
—
0
0
8
33
2.59
1.59
3.4
6.7
24.70
25.08
mmol/l
—
8
33
5
15
3.49
1.55
1.2
2.4
3.14
3.65
g/l
—
5
15
7
28
2.65
1.49
10.9
4.0
22.91
24.34
mmol/l
—
7
28
5
16
3.27
1.46
1.0
2.1
—
—
—
0
0
12
61
2.15
1.42
9.8
3.5
5.97
5.69
kpa
0.46
12
61
0
38
0.00
1.39
0.0
1.1
—
—
—
0
0
5
17
3.07
1.38
1.2
2.5
96.60
88.29
%
—
5
17
8
35
2.43
1.31
3.5
2.4
1.20
2.33
mmol/l
—
8
27
5
19
2.74
1.23
1.6
1.2
—
—
—
0
0
7
32
2.30
1.11
7.7
2.9
1.06
1.41
%
—
7
32
11
62
1.91
1.00
3.3
2.2
414.27
348.72
nmol/l
0.68
11
57
20
139
1.60
0.91
1.5
1.8
451.21
479.86
pmol/l
0.22
14
113
8
44
1.91
0.89
2.5
3.9
4.05
4.63
pmol/l
—
8
38
32
249
1.49
0.89
2.0
1.9
86.61
95.03
pmol/l
0.44
17
117
13
83
1.68
0.81
4.3
2.7
3.00
4.99
e6/l
—
5
43
6
33
1.89
0.81
6.8
3.2
23.30
24.66
mmol/l
—
6
33
0
24
0.00
0.81
0.0
2.3
—
—
—
0
0
65
601
1.56
0.62
26.4
13.5
77.77
80.64
ml/min/173m2
0.46
60
490
0
21
0.00
0.61
0.0
1.2
—
332.87
—
0
9
7
46
1.57
0.50
1.3
1.1
—
174.93
—
0
19
10
68
1.54
0.50
6.7
3.4
—
—
—
0
0
59
630
0.72
0.49
4.7
4.5
4.77
4.72
mmol/l
0.14
51
575
61
646
0.72
0.45
5.5
5.0
2.78
2.78
mmol/l
0.01
53
586
68
701
0.72
0.42
46.4
21.2
127.21
134.49
g/l
3.35
68
685
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.4
—
—
—
0
0
0
17
0.00
0.41
0.0
1.4
—
—
—
0
0
59
624
0.76
0.38
4.7
4.5
1.40
1.52
mmol/l
1.24
51
562
68
654
1.38
0.31
37.9
16.3
139.24
139.76
mmol/l
0.79
68
634
59
557
1.26
0.31
32.4
17.4
14.13
14.93
%
2.34
59
543
34
309
1.18
0.24
5.2
3.9
0.00
0.00
estimate
—
7
51
5
38
1.34
0.24
1.6
2.6
0.08
0.06
e6/l
—
5
38
68
656
1.35
0.23
37.8
16.3
4.07
3.96
mmol/l
3.32
68
635
58
605
0.83
0.22
6.5
5.8
42.75
40.23
mmol/mol
0.93
50
559
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
6
51
1.19
0.20
6.3
5.2
1.19
1.23
mmol/l
—
6
46
19
168
1.17
0.18
6.7
4.3
0.00
0.00
estimate
—
6
49
34
316
1.14
0.17
6.6
5.0
0.00
0.00
estimate
—
7
52
58
600
0.86
0.16
4.7
4.1
1.52
1.27
mmol/l
1.25
49
541
11
95
1.18
0.12
1.5
1.4
—
—
—
0
0
34
321
1.11
0.12
5.2
3.8
0.00
0.00
estimate
—
7
49
40
381
1.11
0.11
2.5
3.2
—
—
—
0
0
42
437
0.91
0.10
3.7
3.1
98.86
49.53
u/l
0.85
36
406
8
77
1.04
0.07
19.3
7.6
—
—
—
0
0
68
668
1.17
0.07
40.8
16.7
83.72
76.01
umol/l
1.11
68
668
10
111
0.89
0.06
1.7
1.6
—
—
—
0
0
25
242
1.05
0.02
6.0
4.1
—
—
—
0
0
63
623
1.07
0.02
5.3
4.5
6.18
5.92
mmol/l
0.69
58
565
11
109
1.01
0.00
1.1
1.3
1.10
13.38
u/ml
—
5
45
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
6.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
9.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
50
1.00
-0.00
3.0
1.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
53
0.94
-0.00
3.2
2.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CARDIOMYOPATHY_DRUGS_OTHER_EXTER_AGENTS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CARDIOMYOPATHY_DRUGS_OTHER_EXTER_AGENTS | 5.804 [3.29, 10.24] | < 0.001 |
| Birth year | 0.991 [0.98, 1.0] | 0.04 |
During the follow-up period (1.1.1998 — 31.12.2019), 70 out of 160 females with CARDIOMYOPATHY_DRUGS_OTHER_EXTER_AGENTS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CARDIOMYOPATHY_DRUGS_OTHER_EXTER_AGENTS | 4.335 [2.25, 8.34] | < 0.001 |
| Birth year | 0.991 [0.98, 1.0] | 0.118 |
During the follow-up period (1.1.1998 — 31.12.2019), 58 out of 136 males with CARDIOMYOPATHY_DRUGS_OTHER_EXTER_AGENTS died.
Mortality risk
Mortality risk for people of age
years, who have CARDIOMYOPATHY_DRUGS_OTHER_EXTER_AGENTS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.329% | 0.929% |
| 5 | 2.531% | 5.604% |
| 10 | 7.054% | 13.748% |
| 15 | 13.192% | 25.687% |
| 20 | 21.35% | 40.197% |
Relationships between endpoints
↥Index endpoint: CARDIOMYOPATHY_DRUGS_OTHER_EXTER_AGENTS – Cardiomyopathy due to drugs and other external agents
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data